---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-032014"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2026-08-10T20:05:52+00:00"
generated_at: "2026-08-10T20:07:28.616302+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Amneal closes $375M cash-plus-stock acquisition of Kashiv BioSciences

## Summary
- Closed Aug 10, 2026; paid $375M cash plus 28,942,098 Class A shares (fractional adjustment).
- Sellers eligible for up to $350M in U.S. regulatory milestone payments for six Kashiv candidates.
- 12-year royalty tail: 25% of gross profits above hurdle amounts for certain products.
- Funded partly via new $350M incremental term loan from Bank of America under Amended Credit Agreement.
- Creates integrated global biosimilars platform; targets $300B+ biologics loss-of-exclusivity over next decade.

## SEC filing metadata
- accession: 0001140361-26-032014
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2026-08-10T20:05:52+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000114036126032014/0001140361-26-032014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000114036126032014/ef20079825_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-032014
- JSON: https://secwatch.observer/filing/0001140361-26-032014.json
- Plain text: https://secwatch.observer/filing/0001140361-26-032014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.